A phase 2, randomized, double-blind study of Ociperlimab (BGB-A1217) and Tislelizumab with chemotherapy in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) without sensitizing EGFR or ALK mutations who have received no previous treatment for metastatic disease
Type d'étude : RIPH1